The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib.
 
Hollis Viray
No Relationships to Disclose
 
Andrew Piper-Vallillo
Consulting or Advisory Role - Genzyme
 
Page Widick
No Relationships to Disclose
 
Emmeline Academia
No Relationships to Disclose
 
Meghan Shea
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); Tesaro/GSK (Inst)
 
Deepa Rangachari
Honoraria - AstraZeneca
Consulting or Advisory Role - Advance Medical; DynaMed
Research Funding - Abbvie/Stemcentrx (Inst); Bristol-Myers Squibb (Inst); Novocure (Inst)
 
Daniel Botelho Costa
Honoraria - Pfizer; Takeda/Millennium
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Janssen Oncology; Takeda/Millennium; Teladoc
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck (Inst); Merrimack (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); Takeda/Millennium (Inst)